Overview
This is an observational study that will include both participants with relapsed/refractory Multiple Myeloma and their doctors. The purpose of this study is to gather information about the use of hematopoietic cell transplantation/HCT and B-cell maturation antigen /BCMS targeted chimeric antigen receptor/CAR autologous T-cell therapy.
Eligibility
Inclusion Criteria:
Patient
- Diagnosis of Multiple Myeloma after January 1, 2017.
- Karnofsky Performance Status > 70%
- ≥ 2 lines of prior therapy
- Anticipated to start new a line of therapy for RRMM within the next 12 months
- Age 18-80 years of age.
- English or Spanish speaking.
- Willing to provide informed consent
- Willing to perform study procedures.
Physician Investigator
- Be a Co-Investigator
- Agree to comply with study procedures
Exclusion Criteria:
Patient
- Active CNS disease
- Patients who already have a definitive plan are to be excluded